PROTEOVANT
LIVE

Serial Number

90858111

Owner

ROIVANT SCIENCES GMBH

Attorney

Allison Strickland Ricketts

Filing Date

Jul 30, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PROTEOVANT Trademark

Serial Number: 90858111 • Registration: 7123854

PROTEOVANT is a trademark filed by ROIVANT SCIENCES GMBH on July 30, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ROIVANT SCIENCES GMBH (69 trademarks)

VIADUKTSTRASSE 8
BASEL 4051 , CH

Entity Type: 27

Trademark Details

Filing Date

July 30, 2021

Registration Date

August 1, 2023

Published for Opposition

May 16, 2023

Goods & Services

Pharmaceutical preparations for human use comprising small molecules for degrading disease-causing cellular proteins for prevention and treatment of oncological, allergy and immunological, neurological, cardiac, dermatological, endocrinological, gastroenterological, hematological, infectious, genetic, nephrological, gynecological, ophthalmological, orthopedic, otorhinolaryngological, podiatric, psychiatric, pulmonological, respiratory, rheumatological, and urological diseases and disorders; biologic preparations for medical and therapeutic purposes comprising small molecules for degrading disease-causing cellular proteins for prevention and treatment of oncological, allergy and immunological, neurological, cardiac, dermatological, endocrinological, gastroenterological, hematological, infectious, genetic, nephrological, gynecological, ophthalmological, orthopedic, otorhinolaryngological, podiatric, psychiatric, pulmonological, respiratory, rheumatological, and urological diseases and disorders; pharmaceutical and biological preparations for treatment and prevention of cancer and for the treatment and prevention of auto-immune diseases and disorders and central nervous system and neurological diseases and disorders

Providing health and medical information; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions

Pharmaceutical product development for new small molecules aimed at degrading disease-causing cellular proteins for treatment in the field of oncology; scientific and technological services, namely, medical research, scientific research and analysis in the field of pharmaceuticals and biomedicine; pharmaceutical and biomedical research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical research and development; providing scientific research information in the field of pharmaceuticals and biomedicine

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 1, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 1, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 16, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 16, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 26, 2023 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Apr 12, 2023 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Apr 7, 2023 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 3, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 17, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 17, 2023 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 17, 2023 ERFR
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Feb 28, 2023 RDX3
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Feb 28, 2023 RDX1
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Feb 28, 2023 RRDX
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2023 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 14, 2023 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 29, 2022 GNFN
FINAL REFUSAL E-MAILED
Nov 29, 2022 GNFR
FINAL REFUSAL WRITTEN
Nov 29, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 28, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 27, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 27, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 27, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 27, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 27, 2022 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Oct 5, 2021 AMPX
ASSIGNED TO LIE
Oct 4, 2021 ALIE
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 27, 2021 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 4, 2021 PARI
NEW APPLICATION ENTERED
Aug 3, 2021 NWAP